X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2197) 2197
Publication (241) 241
Book Chapter (45) 45
Book Review (22) 22
Conference Proceeding (9) 9
Government Document (4) 4
Dissertation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1566) 1566
neurosciences (1409) 1409
rats (958) 958
male (952) 952
parkinson's disease (857) 857
index medicus (736) 736
dopamine (622) 622
humans (570) 570
parkinsons-disease (528) 528
dopamine - metabolism (494) 494
substantia-nigra (479) 479
female (443) 443
nigrostriatal pathway (431) 431
rats, sprague-dawley (408) 408
nigrostriatal system (399) 399
basal ganglia (359) 359
mice (350) 350
disease models, animal (346) 346
neurons (346) 346
corpus striatum - metabolism (335) 335
corpus striatum - drug effects (296) 296
substantia nigra (286) 286
brain (277) 277
substantia nigra - drug effects (274) 274
clinical neurology (265) 265
substantia nigra - metabolism (255) 255
neurology (252) 252
tyrosine 3-monooxygenase - metabolism (252) 252
striatum (240) 240
pharmacology & pharmacy (236) 236
6-hydroxydopamine (231) 231
nigrostriatal (208) 208
immunohistochemistry (204) 204
neurons - metabolism (197) 197
dopamine - physiology (190) 190
neurotrophic factor (190) 190
nervous system (189) 189
rats, wistar (186) 186
nigrostriatal dopaminergic system (184) 184
analysis (182) 182
oxidopamine (182) 182
mptp (180) 180
neurons - drug effects (170) 170
time factors (169) 169
parkinson’s disease (164) 164
article (162) 162
biochemistry & molecular biology (162) 162
neurodegeneration (161) 161
neuroprotection (161) 161
substantia nigra - physiology (161) 161
substantia nigra - pathology (157) 157
in-vivo (156) 156
mice, inbred c57bl (155) 155
motor activity - drug effects (152) 152
parkinson disease - metabolism (148) 148
rat (144) 144
central-nervous-system (140) 140
parkinson disease - physiopathology (140) 140
tyrosine-hydroxylase (137) 137
parkinson disease - pathology (135) 135
corpus striatum - physiology (133) 133
corpus striatum - pathology (132) 132
oxidopamine - toxicity (131) 131
neurons - physiology (127) 127
movement disorders (126) 126
oxidative stress (126) 126
phenols (125) 125
tyrosine hydroxylase (124) 124
rats, inbred strains (122) 122
alpha-synuclein (121) 121
neurodegenerative diseases (120) 120
parkinsons disease (116) 116
rat-brain (112) 112
brain - metabolism (110) 110
dose-response relationship, drug (110) 110
neostriatum (109) 109
parkinson disease - drug therapy (108) 108
gdnf (106) 106
nigrostriatal dopamine system (106) 106
subthalamic nucleus (106) 106
cell biology (103) 103
rat model (99) 99
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (98) 98
behavior, animal - drug effects (98) 98
dopaminergic-neurons (98) 98
substantia nigra - cytology (98) 98
messenger-rna (97) 97
motor activity - physiology (96) 96
tyrosine (95) 95
middle aged (93) 93
ventral tegmental area (93) 93
3,4-dihydroxyphenylacetic acid - metabolism (92) 92
behavioral sciences (92) 92
oxidopamine - pharmacology (90) 90
rodents (90) 90
parkinson disease - therapy (89) 89
aged (88) 88
medicine, research & experimental (87) 87
6-ohda (85) 85
psychiatry (85) 85
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2215) 2215
Spanish (5) 5
French (3) 3
German (3) 3
Japanese (2) 2
Chinese (1) 1
Hungarian (1) 1
Russian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neural Transmission, ISSN 0300-9564, 8/2018, Volume 125, Issue 8, pp. 1251 - 1262
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 04/2009, Volume 156, Issue 7, pp. 1029 - 1040
There is evidence that cannabinoid-based medicines that are selective for different targets in the cannabinoid signalling system (e.g. receptors, inactivation... 
basal ganglia | neuroprotection | basal ganglia disorders | cannabinoids | cannabinoid receptors | movement | symptom relief | Neuroprotection | Basal ganglia | Cannabinoids | Movement | Symptom relief | Basal ganglia disorders | Cannabinoid receptors | TOXICITY IN-VIVO | HUNTINGTONS-DISEASE MICE | RECEPTOR MESSENGER-RNA | GTP-BINDING PROTEINS | RAT STRIATAL NEURONS | LEVODOPA-INDUCED DYSKINESIA | NIGROSTRIATAL DOPAMINERGIC-NEURONS | ACID AMIDE HYDROLASE | CANNABINOID CB1 RECEPTORS | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | Receptor, Cannabinoid, CB2 - agonists | Signal Transduction | Humans | TRPV Cation Channels - agonists | Basal Ganglia - metabolism | Parkinson Disease - drug therapy | Basal Ganglia Diseases - drug therapy | Parkinson Disease - physiopathology | Huntington Disease - metabolism | Cannabinoid Receptor Modulators - physiology | Cannabinoids - therapeutic use | Movement Disorders - metabolism | Movement Disorders - physiopathology | Receptor, Cannabinoid, CB1 - agonists | Basal Ganglia Diseases - physiopathology | Basal Ganglia Diseases - metabolism | Parkinson Disease - metabolism | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Huntington Disease - drug therapy | Endocannabinoids | Huntington Disease - physiopathology | Movement Disorders - drug therapy | Index Medicus | Review
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 07/2019, Volume 402, pp. 100 - 106
The severity of parkinsonism and response to levodopa vary in patients with multiple system atrophy (MSA) because of the heterogeneity of nigrostriatal... 
Parkinsonism | Multiple system atrophy | Nigrostriatal integrity | Cerebellar ataxia | Orthostatic hypotension | DIFFERENTIAL-DIAGNOSIS | INCLUSIONS | NATURAL-HISTORY | DOPAMINE TRANSPORTER | NEUROSCIENCES | CLINICAL NEUROLOGY | F-18-FDG PET | GLUCOSE-METABOLISM | CEREBELLUM | NEUROPATHOLOGY | PARKINSONS-DISEASE | Atrophy
Journal Article